| scholarly article | Q13442814 |
| P2093 | author name string | Roy M. Gulick | |
| P2860 | cites work | Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults | Q24645675 |
| Depletion of latent HIV-1 infection in vivo: a proof-of-concept study | Q28111910 | ||
| Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America | Q28183380 | ||
| Raltegravir with optimized background therapy for resistant HIV-1 infection | Q28288290 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial | Q29620785 | ||
| Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug r | Q31051809 | ||
| Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States | Q33499962 | ||
| Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial | Q33587553 | ||
| Incidence of non-AIDS-defining malignancies in HIV-infected versus noninfected patients in the HAART era: impact of immunosuppression | Q33624504 | ||
| Effect of early versus deferred antiretroviral therapy for HIV on survival | Q33789114 | ||
| Interleukin-2 therapy in patients with HIV infection | Q33847543 | ||
| The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy | Q33959260 | ||
| Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study | Q34011661 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study | Q34464169 | ||
| Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection | Q34597895 | ||
| Changes in the risk of death after HIV seroconversion compared with mortality in the general population | Q34791057 | ||
| Maraviroc for previously treated patients with R5 HIV-1 infection | Q34806062 | ||
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies | Q36285986 | ||
| Early versus standard antiretroviral therapy for HIV-infected adults in Haiti | Q36914021 | ||
| Management of patients with the immune reconstitution inflammatory syndrome | Q37546240 | ||
| Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis | Q37718319 | ||
| Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel | Q37773748 | ||
| The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients | Q40039677 | ||
| Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis | Q42623275 | ||
| Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st | Q43208808 | ||
| High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial | Q43265110 | ||
| Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. | Q43265351 | ||
| Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials | Q43285218 | ||
| Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection. | Q43298626 | ||
| Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group | Q43898486 | ||
| Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team | Q44088437 | ||
| Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia | Q44457921 | ||
| The prevalence and incidence of neurocognitive impairment in the HAART era. | Q44520627 | ||
| Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy | Q45760702 | ||
| Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study | Q46241827 | ||
| Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries | Q46391119 | ||
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
| Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. February 5, 2001. | Q53991841 | ||
| British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 | Q57180178 | ||
| Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. Fédération National des Centres de Lutte contre le SIDA | Q73815436 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | anti-retroviral agent | Q50430310 |
| P304 | page(s) | S43-8 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | Antiretroviral treatment 2010: progress and controversies | |
| P478 | volume | 55 Suppl 1 |
| Q30387318 | Applying evolutionary biology to address global challenges |
| Q35996572 | Complications of common gynecologic surgeries among HIV-infected women in the United States |
| Q34460060 | DNA sequencing and bar-coding using solid-state nanopores |
| Q42248267 | Direct monthly highly active antiretroviral therapy supply - a method to increase patient's adherence and outcome. Experience of one AIDS centre in Israel |
| Q41481676 | Factors contributing to antiretroviral drug adherence among adults living with HIV or AIDS in a Kenyan rural community |
| Q36028395 | Medication-related barriers to entering HIV care |
| Q34299007 | National and international policies to mitigate disease threats |
| Q26995310 | Pharmacological inhibition of feline immunodeficiency virus (FIV) |
| Q34780130 | Prevention and treatment of HIV/AIDS among drug-using populations: a global perspective |
| Q40819527 | Risk Factors for HIV Acquisition in a Prospective Nairobi-Based Female Sex Worker Cohort |
| Q35992621 | Translational research in infectious disease: current paradigms and challenges ahead |
| Q36302253 | Use of and Adherence to Antiretroviral Therapy in a Large U.S. Sample of HIV-infected Adults in Care, 2007-2008. |
Search more.